Peak Bio, a South Korean clinical-stage biopharmaceutical company, has agreed to go public on Nasdaq through a merger with blank cheque company Ignyte Acquisition Corp in a deal that values the combined business at $278 million.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
